Role of aramchol in steatohepatitis and fibrosis in mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD) that sets the stage for further liver damage. The mechanism for the progression of NASH involves multiple parallel hits, including oxidative stress, mitochondrial dysfunction, inflammation, and others. Manipulation of any of these pathways may be an approach to prevent NASH development and progression. Arachidyl‐amido cholanoic acid (Aramchol) is presently in a phase IIb NASH study. The aim of the present study was to investigate Aramchol's mechanism of action and its effect on fibrosis using the methionine‐ and choline‐deficient (MCD) diet model of NASH. We collected liver and serum from mice fed an MCD diet containing 0.1% methionine (0.1MCD) for 4 weeks; these mice developed steatohepatitis and fibrosis. We also collected liver and serum from mice receiving a control diet, and metabolomes and proteomes were determined for both groups. The 0.1MCD‐fed mice were given Aramchol (5 mg/kg/day for the last 2 weeks), and liver samples were analyzed histologically. Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD‐fed mice. Aramchol down‐regulated stearoyl‐coenyzme A desaturase 1, a key enzyme involved in triglyceride biosynthesis and the loss of which enhances fatty acid β‐oxidation. Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/oxidized GSH ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD‐fed mice and patients with NAFLD showed a substantial overlap. Conclusion: Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing stearoyl‐coenyzme A desaturase 1 and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. We also demonstrated that the 0.1MCD model resembles the metabolic phenotype observed in about 50% of patients with NAFLD, which supports the potential use of Aramchol in NASH treatment. (Hepatology Communications 2017;1:911–927)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 3×
“NASH is a progressive disease that can lead to further liver injury, advanced fibrosis, cirrhosis, and hepatocellular carcinoma.((1,2)) During the last decades, the incidence of NAFLD has multiplied, and it is now the most common disease of the liver, with a prevalence between 10% and 40% in Western countries”
BackgroundNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“The reduction of MUFAs agrees with Aramchol’s mechanism of action, whereas the increase in lysophospholipid species has been associated with lipotoxicity and NASH progression.((40,41)) Although it is at present not known if these noninvasive biomarkers of Aramchol’s administration could be translated to determine the…”
BackgroundMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves
Gomez-Sanchez, J. A., Carty, L., Iruarrizaga-Lejarreta, M., Palomo-Irigoyen, M., Varela-Rey, M., Griffith, M., Hantke, J., Macias-Camara, N., Azkargorta, M., Aurrekoetxea, I., et al. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201503019 · Cited by 453 · cited 1×
“Acquisition of data and differential protein analysis were carried out as described.((22)) Briefly, peptide mixtures were separated on a nanoACQUITY ultra performance liquid chromatography system (Waters Corp.”
MethodSelf-citationGene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427 · cited 5×
“1MCD-fed mice involved in lipid metabolism revealed that the content of fatty acid translocase (CD36), an FA transporter with an overexpression that correlates with TG accumulation in human NAFLD,((27)) was augmented whereas the content of SCD1 was reduced (Fig.”
BackgroundInfluentialMetabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Self-citationTeufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., von Schönfels, W., Herrmann, A., Brückner, S., Stickel, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.051 · Cited by 229 · cited 2×
“Comparison of gene expression patterns among various murine models of NASH and liver tissues from patients with NAFLD has shown little overlap.((32)) These models included a high-fat/high-carbohydrate diet, high-fat/high-carbohydrate/streptozocin diet, Western-type diet, Pten, and MCD diet.”
BackgroundResultPPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells
Zhao, C., Chen, W., Yang, L., Chen, L., Stimpson, S. A., & Diehl, A. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.069 · Cited by 139
Cited by
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Self-citationNuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
“Those beneficial effects were observed in several experimental models leading to further assessment in clinical studies [235,236].”
Background
Metadata
- Authors
- Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simon, J., Gutiérrez‐de Juan, V., delaCruz‐Villar, L., Azkargorta, M., Lavin, J. L., Mayo, R., Van Liempd, S. M., Aurrekoetxea, I., Buqué, X., Delle Cave, D., Peña, A., Rodríguez‐Cuesta, J., Aransay, A. M., Elortza, F., Falcón‐Pérez, J. M., Aspichueta, P., Hayardeny, L., Noureddin, M., Sanyal, A. J., Alonso, C., Anguita, J., Martínez‐Chantar, M. L., Lu, S. C., & Mato, J. M.
- Venue
- Hepatology Communications
- Published
- 2017-10-04
- Volume
- 1
- Issue
- 9
- Pages
- 911-927
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2761787658
- Cited by
- 113
- References
- 10
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.